MAIA Biotechnology Inc. (MAIA)
2.18
-0.09 (-3.96%)
At close: Jan 14, 2025, 3:59 PM
2.21
1.38%
After-hours Jan 14, 2025, 08:00 PM EST
undefined% (undefined)
| Bid | 2.14 |
| Market Cap | 55.22M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.34 |
| PE Ratio (ttm) | -1.63 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 2.34 |
| Volume | 183,976 |
| Avg. Volume (20D) | 244,498 |
| Open | 2.28 |
| Previous Close | 2.27 |
| Day's Range | 2.15 - 2.29 |
| 52-Week Range | 0.99 - 5.99 |
| Beta | undefined |
About MAIA
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois....
Industry Biotechnology
Sector Healthcare
IPO Date Jul 28, 2022
Employees 13
Stock Exchange AMEX
Ticker Symbol MAIA
Website https://www.MAIABiotech.com
1 week ago ·
Source
+15.53%
MAIA Biotechnology shares are trading higher after...
Unlock content with
Pro Subscription
7 months ago ·
Source
-26.27%
MAIA Biotechnology shares are trading lower. The company reported new clinical data from its Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor cemiplimab in patients with advanced non-small cell lung cancer who failed 2 or more standard-of-care therapy regimens.
1 month ago · businesswire.com
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade GliomasCHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas.
